KAPA Kairos Pharma Ltd: חובות לטווח קצר של החברה

Kairos Pharma Ltd (KAPA) is attracting leading scientists to combat drug resistance. The amount of short-term debt capital on the GURU.Markets interface is shown on this chart, where the 0.00 metric indicates the status of liabilities. Kairos Pharma Ltd (KAPA) aims to become the standard of care for lung and prostate cancer, leveraging patient inflows from US oncology centers under strict FDA oversight.

This indicator is critical for liquidity stress testing and assessing the issuer's solvency as part of fundamental screening. The company's short-term debt measures the total obligations with a maturity horizon of up to one year, while the short-term debt dynamics for Kairos Pharma (KAPA) reflect the rate of capital consumption during the clinical trials of oncology platforms and the risks associated with dependence on clinical trial results.